Citations (23)
Keep up to date with the latest research on this topic with citation updates for this article.
Read on this site (3)
Eveline Lefever, Joke Vliebergh & Chantal Mathieu. (2021) Improving the treatment of patients with diabetes using insulin analogues: current findings and future directions. Expert Opinion on Drug Safety 20:2, pages 155-169.
Read now
Read now
Deep Dutta, Deepak Khandelwal & Sanjay Kalra. (2020) Injectable combination therapies for the management of diabetes: an Indian perspective. Expert Opinion on Drug Metabolism & Toxicology 16:3, pages 209-216.
Read now
Read now
Sarah Eggert, Esther Zimmermann & Kamilla Begtrup. (2018) Methodological concerns with the meta-analysis comparing insulin degludec/liraglutide and insulin glargine/lixisenatide. Expert Opinion on Pharmacotherapy 19:4, pages 317-318.
Read now
Read now
Articles from other publishers (20)
Gergely Á. Visolyi, Beatrix A. Domján, Márk M. Svébis, Anna Péterfi, Barbara D. Lovász, Szilvia Mészáros, Viktor J. Horváth & Ádám G. Tabák. (2023) Comparison of Efficacy and Safety of Commercially Available Fixed-Ratio Combinations of Insulin Degludec/Liraglutide and Insulin Glargine/Lixisenatide: A Network Meta-analysis. Canadian Journal of Diabetes 47:4, pages 368-377.
Crossref
Crossref
Hernando Vargas-Uricoechea, Juan Pablo Frias & Hernando David Vargas-Sierra. (2023) Fixed-ratio Combinations (basal Insulin Plus GLP-1RA) In Type 2 Diabetes. an Analytical Review Of Pivotal Clinical Trials. Review of Diabetic Studies 19:1, pages 14-27.
Crossref
Crossref
Ivona Risovic, Mirjana Sumarac Dumanovic, Mirjana Bojic & Danijel Djekic. (2023) Direct comparison two fixed-ratio combination glucagon-like peptide receptor agonist and basal insulin on glycemic and non glycemic parameters in type 2 diabetes. BMC Endocrine Disorders 23:1.
Crossref
Crossref
Zhi-Yuan Dong, Ji-Hua Feng & Jian-Feng Zhang. (2022) Efficacy and Tolerability of Insulin Degludec Versus Other Long-acting Basal Insulin Analogues in the Treatment of Type 1 and Type 2 Diabetes Mellitus: A Systematic Review and Meta-analysis. Clinical Therapeutics 44:11, pages 1520-1533.
Crossref
Crossref
Sándor Szépkúti, Szilvia Bandur, Gábor Kovács, Tamás Ferenci, Márk M. Svébis, Piroska Turbucz & Ádám G. Tabák. (2022) Real-world effectiveness of IDegLira compared with intensified conventional insulin therapy in adults with type 2 diabetes: a retrospective cohort study. BMC Endocrine Disorders 22:1.
Crossref
Crossref
Fernando Gomez‐Peralta, Ebaa Al‐Ozairi, Edward B. Jude, Xiaoying Li & Julio Rosenstock. (2021) Titratable fixed‐ratio combination of basal insulin plus a glucagon‐like peptide‐1 receptor agonist: A novel, simplified alternative to premix insulin for type 2 diabetes. Diabetes, Obesity and Metabolism 23:7, pages 1445-1452.
Crossref
Crossref
Poobalan Naidoo, Celia Bouharati, Virendra Rambiritch, Sumanth Karamchand, Barbara A Tafuto & Rory F Leisegang. (2021) Glycated haemoglobin reduction and fixed ratio combinations of analogue basal insulin and glucagon-like peptide-1 receptor agonists: A systematic review. World Journal of Meta-Analysis 9:3, pages 297-308.
Crossref
Crossref
Giuseppe Lisco, Anna De Tullio, Edoardo Guastamacchia & Vincenzo Triggiani. (2021) Fixed-Ratio Combinations of Basal Insulin and GLP-1RA in the Management of Type 2 Diabetes Mellitus: Highlights from the Literature. Endocrine, Metabolic & Immune Disorders - Drug Targets 21:4, pages 626-646.
Crossref
Crossref
Daniel Christopher Rainkie, Zeinab Salman Abedini & Nada Nabil Abdelkader. (2020) Reporting and methodological quality of systematic reviews and meta-analysis with protocols in Diabetes Mellitus Type II: A systematic review. PLOS ONE 15:12, pages e0243091.
Crossref
Crossref
Francesco Giorgino, Irene Caruso & Raffaele Napoli. (2020) Titratable fixed-ratio combination of insulin glargine plus lixisenatide: A simplified approach to glycemic control in type 2 diabetes mellitus. Diabetes Research and Clinical Practice 170, pages 108478.
Crossref
Crossref
Philip Home, Lawrence Blonde, Sanjay Kalra, Linong Ji, Patricia Guyot, Claire Brulle‐Wohlhueter, Erin Murray, Roshan Shah, Toby Sayre & Alka Shaunik. (2020)
Insulin glargine/lixisenatide fixed‐ratio combination (
iGlarLixi
) compared with premix or addition of meal‐time insulin to basal insulin in people with type 2 diabetes: A systematic review and Bayesian network meta‐analysis
. Diabetes, Obesity and Metabolism 22:11, pages 2179-2188.
Crossref
Crossref
Philip D. Home, Vanita R. Aroda, Lawrence Blonde, Patricia Guyot, Alka Shaunik, Mir Sohail Fazeli, Hardik Goswami, Sanjay Kalra & Mir‐Masoud Pourrahmat. (2020)
Efficacy and safety of
iGlarLixi
versus
IDegLira
in adults with type 2 diabetes inadequately controlled by glucagon‐like peptide‐1 receptor agonists: a systematic literature review and indirect treatment comparison
. Diabetes, Obesity and Metabolism 22:11, pages 2170-2178.
Crossref
Crossref
Jessica A. Huthmacher, Juris J. Meier & Michael A. Nauck. (2020) Efficacy and Safety of Short- and Long-Acting Glucagon-Like Peptide 1 Receptor Agonists on a Background of Basal Insulin in Type 2 Diabetes: A Meta-analysis. Diabetes Care 43:9, pages 2303-2312.
Crossref
Crossref
Ivan I. Dedov, Marina V. Shestakova, Alexander Y. Mayorov, Minara S. Shamkhalova, Olga Yu. Sukhareva, Gagik R. Galstyan, Alla Y. Tokmakova, Tatiana V. Nikonova, Elena V. Surkova, Irina V. Kononenko, Daria N. Egorova, Lyudmila I. Ibragimova, Ekaterina A. Shestakova, Inna I. Klefortova, Igor A. Sklyanik, Ivona Ya. Yarek-Martynova, Anastasia S. Severina, Sergey A. Martynov, Olga K. Vikulova, Viktor Y. Kalashnikov, Irina Z. Bondarenko, Irina S. Gomova, Elena G. Starostina, Alexander S. Ametov, Mikhail B. Antsiferov, Tatiana P. Bardymova, Irina A. Bondar, Farida V. Valeeva, Tatiana Y. Demidova, Ashot M. Mkrtumyan, Nina A. Petunina, Lyudmila A. Ruyatkina, Lyudmila A. Suplotova, Olga V. Ushakova & Yurii Sh. Khalimov. (2020) Diabetes mellitus type 2 in adults. Diabetes mellitus 23:2S, pages 4-102.
Crossref
Crossref
Young-A Heo. (2020) Insulin degludec/liraglutide in type 2 diabetes: a profile of its use. Drugs & Therapy Perspectives 36:6, pages 219-229.
Crossref
Crossref
Emma Deeks. (2019) Insulin glargine/lixisenatide in type 2 diabetes: a profile of its use. Drugs & Therapy Perspectives 35:10, pages 470-480.
Crossref
Crossref
Leigh Perreault, Helena Rodbard, Virginia Valentine & Eric Johnson. (2019) Optimizing Fixed-Ratio Combination Therapy in Type 2 Diabetes. Advances in Therapy 36:2, pages 265-277.
Crossref
Crossref
David M. Williams, Natasha Shrikrishnapalasuriyar, Waheeba Syed, Win L. Yin, Richard Chudleigh, Stephen C. Bain, David E. Price & Jeffrey W. Stephens. (2018) Real-world clinical experience of Xultophy in the management of patients with type 2 diabetes in a secondary care clinic. Diabetes & Metabolic Syndrome: Clinical Research & Reviews 12:6, pages 1079-1082.
Crossref
Crossref
Lawrence Blonde, Luigi Meneghini, Xuejun Victor Peng, Anders Boss, Kyu Rhee, Alka Shaunik, Supriya Kumar, Sidhartha Balodi, Claire Brulle-Wohlhueter & Rory J. McCrimmon. (2018) Probability of Achieving Glycemic Control with Basal Insulin in Patients with Type 2 Diabetes in Real-World Practice in the USA. Diabetes Therapy 9:3, pages 1347-1358.
Crossref
Crossref
Taylor R. Inman, Erika Plyushko, Nicholas P. Austin & Jeremy L. Johnson. (2018) The role of basal insulin and GLP-1 receptor agonist combination products in the management of type 2 diabetes. Therapeutic Advances in Endocrinology and Metabolism 9:5, pages 151-155.
Crossref
Crossref